Drug-target network

Nature Biotechnology

Volumn 25, Issue 10, 2007, Pages 1119-1126

  Yildirim, Muhammed A ^a,b,c   Goh, Kwang Il ^a,d,e   Cusick, Michael E ^a,b   Barabási, Albert László ^a,d,f   Vidal, Marc ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF NOTRE DAME   (United States)

^e Korea University   (South Korea)

^f NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANATOMICAL THERAPEUTIC CHEMICAL CLASSIFICATION; DISEASE-GENE PRODUCTS; PALLIATIVE DRUGS; PROTEIN-PROTEIN INTERACTION;

BIOTECHNOLOGY; GENES; GRAPH THEORY; PROTEINS;

DRUG PRODUCTS;

ABARELIX; ALPHA 1 ADRENERGIC RECEPTOR; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; CARMUSTINE; CHOLINERGIC RECEPTOR; DOPAMINE 2 RECEPTOR; GENE PRODUCT; HISTAMINE H1 RECEPTOR; IMATINIB; OLANZAPINE; PROMAZINE; PROPIOMAZINE; PROTEIN; RECLAST; SUNITINIB; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOLEDRONIC ACID;

ANIMAL CELL; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; MOUSE; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL;

COMPUTER SIMULATION; DATABASES, FACTUAL; GENE EXPRESSION REGULATION; GENOMICS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 35148838537     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1338     Document Type: Article

References (37)

1. Hopkins, A.L. & Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 1, 727-730 (2002).
2. Imming, P., Sinning, C. & Meyer, A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5, 821-834 (2006).
3. Overington, J.P., Bissan, A. & Hopkins, A. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996 (2006).
4. Russ, A.P. & Lampel, S. The druggable genome: an update. Drug Discov. Today 10, 1607-1610 (2005).
5. Drews, J. Stategic trends in the drug industry. Drug Discov. Today 8, 411-420 (2003).
6. Barabasi, A.L. & Oltvai, Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 5, 101-113 (2004).
7. Han, J.-D. et al. Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature 430, 88-93 (2004).
8. Jeong, H., Mason, S., Barabasi, A.-L. & Oltvai, Z. Lethality and centrality in protein networks. Nature 411, 41-42 (2001).
9. Vidal, M. Interactome modeling. FEBS Lett. 579, 1834-1838 (2005).
10. Goh, K.I. et al. The human disease network. Proc. Natl. Acad. Sci. USA 104, 8685-8690 (2007).
11. Jimenez-Sanchez, G., Childs, B. & Valle, D. Human disease genes. Nature 409, 853-855 (2001).
12. Peltonen, L. & McKusick, V. Dissecting human disease in the postgenomic era. Science 291, 1224-1229 (2001).
13. Wishart, D.S. et al. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668-D672 (2006).
14. Paolini, G.V., Shapland, R.H., van Hoorn, W.P., Mason, J.S. & Hopkins, A.L. Global mapping of pharmacological space. Nat. Biotechnol. 24, 805-815 (2006).
15. Roth, B.L., Sheffler, D.J. & Kroeze, W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353-359 (2004).
16. Hopkins, A.L., Mason, J.S. & Overington, J.P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127-136 (2006).
17. Mencher, S.K. & Wang, L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin. Pharmacol. 5, 3 (2005).
18. Newman, M.E. Scientific collaboration networks. I. Network construction and fundamental results. Phys. Rev. E 64, 016131 (2001).
19. Cokol, M., Iossifov, I., Weinreb, C. & Rzhetsky, A. Emergent behavior of growing knowledge about molecular interactions. Nat. Biotechnol. 23, 1243-1247 (2005).
20. Rual, J.-F. et al. Toward a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173-1178 (2005).
21. Stelzl, U. et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 122, 957-968 (2005).
22. Eppig, J.T. et al. The Mouse Genome Database (MGD): from genes to mice-a community resource for mouse biology. Nucleic Acids Res. 33, D471-D475 (2005).
23. Hartwell, L.H., Hopfield, J.J., Leibler, S. & Murray, A.W. From molecular to modular cell biology. Nature 402, C47-C52 (1999).
24. Ge, X. et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 86, 127-141 (2005).
25. Hamosh, A., Scott, A.F., Amberger, J.S., Bocchini, C.A. & McKusick, V.A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33, D514-D517 (2005).
26. Butcher, E.C., Berg, E. & Kunkel, E. Systems biology in drug discovery. Nat. Biotechnol. 22, 1253-1259 (2004).
27. Chanda, S.K. & Caldwell, J. Fulfilling the promise: drug discovery in the postgenomic era. Drug Discov. Today 8, 168-174 (2003).
28. Searls, D.B. Pharmacophylogenomics: genes, evolution and drug targets. Nat. Rev. Drug Discov. 2, 613-623 (2003).
29. van der Greef, J. & McBurney, R. Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov. 4, 961-967 (2005).
30. Lindpaintner, K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1, 463-469 (2002).
31. Gershell, L.J. & Atkins, J. A brief history of novel drug discovery technologies. Nat. Rev. Drug Discov. 2, 321-327 (2003).
32. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
33. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493-502 (2002).
34. Babu, M.M., Luscombe, N.M., Aravind, L., Gerstein, M. & Teichmann, S.A. Structure and evolution of transcriptional regulatory networks. Curr. Opin. Struct. Biol. 14, 283-291 (2004).
35. Lee, T.-I. et al. Transcriptional regulatory networks in Saccharomyces cerevisiae. Science 298, 799-804 (2002).
36. Rodriguez-Caso, C., Medina, M.A. & Sole, R.V. Topology, tinkering and evolution of the human transcription factor network. FEBS J. 272, 6423-6434 (2005).
37. Wagner, A. & Fell, D.A. The small world inside large metabolic networks. Proc. Biol. Sci. 268, 1803-1810 (2001).